Porównaj metody

	MSFC: Multiple Sclerosis Functional Composite	MDS-UPDRS	RMI: Rivermead Mobility Index
Dziedzina	Neurologia	Neurologia	Neurologia
Rodzina	Process / pipeline	Process / pipeline	Process / pipeline
Rok powstania	1999	2008	1991
Twórca	Gary Cutter, Richard Rudick, and NMSS Consortium	Christopher G. Goetz and Movement Disorder Society	Frank Collen, Derick Wade, and Rivermead Rehabilitation Centre
Typ	Clinician-administered performance test	Clinician-rated	Clinician-observed performance test
Źródło pierwotne	Cutter, G. R., Baier, M. L., Rudick, R. A., et al. (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Multiple Sclerosis, 5(4), 244-250.	Goetz, C. G., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129-2170.	Collen, F. M., Wade, D. T., Robb, G. F., Bradshaw, C. M. (1991). The Rivermead Mobility Index: A further development of the Rivermead Motor Assessment. International Disability Studies, 13(2), 50-54.
Inne nazwy	MS Functional Composite	UPDRS	Rivermead Mobility Index
Pokrewne	4	5	5
Podsumowanie	The Multiple Sclerosis Functional Composite (MSFC) is an objective, performance-based assessment of MS-related disability capturing three key functional domains: lower extremity mobility, upper extremity coordination, and cognitive/processing speed. Developed in 1999 by the National MS Society and adopted widely in clinical trials, the MSFC provides quantifiable endpoints complementing the Expanded Disability Status Scale (EDSS). The three-component design addresses EDSS limitations by including cognition and standardizing measurement via timed tasks.	The MDS-UPDRS is the gold-standard clinician-administered rating scale for assessing motor and non-motor manifestations of Parkinson's disease. Developed by the Movement Disorder Society in 2008 to enhance the original UPDRS, it measures disease severity across daily living, motor function, and treatment complications. Used globally in clinical trials, longitudinal cohort studies, and routine neurological practice.	The Rivermead Mobility Index (RMI) is a brief, clinician-observed performance test of basic mobility abilities developed for assessing stroke and neurological rehabilitation outcomes. Published in 1991 by Frank Collen and colleagues at Rivermead Rehabilitation Centre (Oxford, UK), the 15-item index measures bed mobility, sitting/standing balance, transfers, and ambulation. The RMI is widely used in stroke units and rehabilitation settings to track functional recovery and predict discharge outcomes.